Core Viewpoint - Shanghai Sailun Biotechnology Co., Ltd. has reported on the management and usage of raised funds for the first half of 2025, detailing the total amount raised, expenditures, and remaining balances in compliance with regulatory requirements [1][2]. Fundraising Overview - The company raised a total of RMB 89,379.18 million by issuing 27.06 million shares at a price of RMB 33.03 per share, with all funds received by March 4, 2022 [1]. - As of June 30, 2025, the cumulative usage of raised funds amounted to RMB 283,688,338.64, leaving a balance of RMB 559,847,593.49 [1][2]. Fund Management - The company has established a fundraising management system to ensure the effective use of raised funds, adhering to relevant laws and regulations [1]. - A tripartite supervision agreement has been signed with various banks to ensure the proper management of the funds [1][2]. Fund Usage Details - The company has utilized raised funds for specific projects, including: - Special drug and innovative technology research: RMB 6,080,130.83 - Emergency drug network service project: RMB 5,651,013.32 - Factory expansion project: RMB 28,113,571.80 - The total balance in the fundraising account as of June 30, 2025, was RMB 559,847,593.49 after accounting for expenditures and income from financial products [1][2]. Idle Fund Management - The company approved the use of up to RMB 550 million of temporarily idle funds for cash management, with a balance of RMB 490 million invested in structured deposits as of June 30, 2025 [2][5]. - The company has generated income from cash management activities while ensuring that project construction and fund safety are not compromised [2][5]. Surplus Fund Usage - Surplus funds from the completed emergency drug network service project, amounting to RMB 7,851,987.11, will be permanently used to supplement the company's working capital [2][5]. - The company has not encountered any changes in the use of raised funds or any violations in fund management [2][5].

证券代码：688163 证券简称：赛伦生物 公告编号：2025-015 上海赛伦生物技术股份有限公司 关于部分募集资金投资项目结项并将节余募集资金 永久补充流动资金以及注销相关募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）首次公开发行股票募 投项目"急（抢）救药物急救网络服务项目"已完成建设并达到预定可使用状态， 公司决定将其结项后的节余募集资金永久补充流动资金，同时注销相关募集资金 专户。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向 社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 元，募集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部到 位，并存放于募集资金专项账户内。天职国际会计师事务所（特殊普通合伙）于 资金实施专户存储、专 ...